Jo E Lewis, Danae Nuzzaci, Paula-Peace James-Okoro, Mireia Montaner, Elisabeth O'Flaherty Rottenberger, Tamana Darwish, Marito Hayashi, Stephen D Liberles, David Hornigold, Jacqueline Naylor, David Baker, Fiona M Gribble, Frank Reimann
OBJECTIVE: Glucose dependent insulinotropic polypeptide (GIP) is well established as an incretin hormone, boosting glucose-dependent insulin secretion. However, whilst anorectic actions of its sister-incretin glucagon-like peptide-1 (GLP-1) are well established, a physiological role for GIP in appetite regulation is controversial, despite the superior weight loss seen in preclinical models and humans with GLP-1/GIP dual receptor agonists compared with GLP-1R agonism alone. METHODS: We generated a mouse model in which GIP expressing K-cells can be activated through hM3Dq Designer Receptor Activated by Designer Drugs (DREADD, GIP-Dq) to explore physiological actions of intestinally-released GIP...
April 21, 2024: Molecular Metabolism